Verastem (VSTM) Non-Current Debt (2017 - 2026)
Verastem (VSTM) recorded quarterly Non-Current Debt of $73.1 million in Q1 2026, down 4.21% quarter-over-quarter from $76.3 million in Q4 2025, and up 2.3% on a YoY basis from $71.5 million in Q1 2025.
Verastem (VSTM) Non-Current Debt (2017 - 2026) Analysis & Trends
Verastem's Non-Current Debt history runs 9 years deep, the most recent figure standing at $73.1 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 2.3% year-over-year to $73.1 million; the TTM figure through Mar 2026 stood at $73.1 million (up 2.3% YoY), while the FY2025 annual figure was $76.3 million, up 87.43% from the prior year.
- Non-Current Debt was $73.1 million for Q1 2026 at Verastem, down from $76.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $78.1 million in Q3 2025 to a low of $24.2 million in Q1 2022.
- Historically, Non-Current Debt has averaged $45.7 million across 5 years, with a median of $39.9 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt retreated 23.21% in 2024, then surged 154.92% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $24.5 million in 2022, then jumped by 63.44% to $40.1 million in 2023, then increased by 1.59% to $40.7 million in 2024, then soared by 87.43% to $76.3 million in 2025, then dropped by 4.21% to $73.1 million in 2026.
- The last three Non-Current Debt figures came in at $73.1 million (Q1 2026), $76.3 million (Q4 2025), and $78.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | 73.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.12 Mn |
| Mar 31, 2026 | 73.12 Mn |
| Dec 31, 2025 | 76.33 Mn |
| Dec 31, 2025 | 76.33 Mn |
| Sep 30, 2025 | 78.12 Mn |
| Sep 30, 2025 | 78.12 Mn |
| Jun 30, 2025 | 74.27 Mn |
| Jun 30, 2025 | 74.27 Mn |
| Mar 31, 2025 | 71.48 Mn |
| Mar 31, 2025 | 71.48 Mn |
| Dec 31, 2024 | 40.72 Mn |
| Dec 31, 2024 | 40.72 Mn |
| Sep 30, 2024 | 30.65 Mn |
| Sep 30, 2024 | 30.65 Mn |
| Jun 30, 2024 | 35.39 Mn |
| Jun 30, 2024 | 35.39 Mn |
| Mar 31, 2024 | 40.12 Mn |
| Mar 31, 2024 | 40.12 Mn |
| Dec 31, 2023 | 40.09 Mn |
| Dec 31, 2023 | 40.09 Mn |